LLY has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
LLY has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2024-10-31), Eli Lilly and Co's share price is $829.74. Eli Lilly and Co's Tangible Book per Share of Sep. 2024 for the quarter that ended in Sep. 2024 was $2.14. Hence, Eli Lilly and Co's Price to Tangible Book Ratio of today is 388.27.
The historical rank and industry rank for Eli Lilly and Co's Price-to-Tangible-Book or its related term are showing as below:
During the past 13 years, Eli Lilly and Co's highest Price to Tangible Book Ratio was 10731.88. The lowest was 5.59. And the median was 16.54.
A closely related ratio is called PB Ratio. As of today, Eli Lilly and Co's share price is $829.74. Eli Lilly and Co's Book Value per Sharefor the quarter that ended in Sep. 2024 was $15.74. Hence, Eli Lilly and Co's P/B Ratio of today is 52.73.
The historical data trend for Eli Lilly and Co's Price-to-Tangible-Book can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Eli Lilly and Co Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Price-to-Tangible-Book | Get a 7-Day Free Trial | - | - | - | - | - |
Eli Lilly and Co Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
Price-to-Tangible-Book | Get a 7-Day Free Trial | 1,443.90 | - | 630.95 | 704.03 | - |
For the Drug Manufacturers - General subindustry, Eli Lilly and Co's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, Eli Lilly and Co's Price-to-Tangible-Book distribution charts can be found below:
* The bar in red indicates where Eli Lilly and Co's Price-to-Tangible-Book falls into.
Eli Lilly and Co's price-to-tangible-book ratio for today is calculated as:
Price to Tangible Book | = | Share Price | / | Tangible Book per Share (Q: Sep. 2024 ) |
= | 829.74 | / | 2.137 | |
= | 388.27 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Price to Tangible Book | = | Market Cap | / | Tangible Equity | ||||
= | Market Cap | / | (Total Stockholders Equity | - | Preferred Stock | - | Intangible Assets) |
A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.
Thank you for viewing the detailed overview of Eli Lilly and Co's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.
Lilly Endowment Inc | 10 percent owner | 2801 NORTH MERIDIAN ST, INDIANAPOLIS IN 46208 |
Donald A Zakrowski | officer: Chief Accounting Officer | LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285 |
Johna Norton | officer: Senior VP, Global Quality | LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285 |
Alonzo Weems | officer: SVP, ERM & CECO | LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285 |
Patrik Jonsson | officer: SVP and Pres., Lilly Bio-Meds | LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285 |
Anne E. White | officer: SVP & Pres-Lilly Oncology | LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285 |
Eric Dozier | officer: EVP, HR & Diversity | LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285 |
Jackson P Tai | director | |
Mary Lynne Hedley | director | C/O TESARO, INC., 1000 WINTER ST., STE 3300, WALTHAM MA 02451 |
Marschall S Runge | director | LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285 |
Naarden Jacob Van | officer: SVP, CEO LoxoONC, Pres LlyONC | C/O ELI LILLY & CO, LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285 |
Diogo Rau | officer: SVP & CIDO | LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285 |
Edgardo Hernandez | officer: SVP & Pres., Mfg. Operations | LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285 |
Kimberly H Johnson | director | C/O FANNIE MAE, 1100 15TH STREET, NW, WASHINGTON DC 20005 |
Anat Ashkenazi | officer: SVP & CFO | LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285 |
From GuruFocus
By GuruFocus Research • 08-08-2024
By GuruFocus Research • 09-20-2024
By PRNewswire • 08-20-2024
By PRNewswire • 07-02-2024
By PRNewswire • 09-24-2024
By PRNewswire • 09-12-2024
By PRNewswire • 07-25-2024
By PRNewswire • 09-04-2024
By PRNewswire • 06-25-2024
By PRNewswire • 08-13-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.